For research use only. Not for use in humans.

Mepolizumab (Anti-IL-5)

Synonyms: IL5, BCGFII

Mepolizumab (Anti-IL-5) is a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against interleukin-5 (IL-5) with anti-asthmatic and potential immunosuppressive activity. MW: 145.5 kD.

Mepolizumab (Anti-IL-5)

Quality Control

Batch: A242801 Purity: 99% Protein concentration: 17.864mg/ml Endotoxin Level: <1EU/mg
99

Specificity

Name Citation IL-6 IL-1 IL-8 IL-12 IL-10 IL-13 IL-2 Others
SKF-86002 1
JTE-607 Dihydrochloride 2 TNF-alpha
A-740003 2 rat P2X7 receptor,human P2X7 receptor
Apilimod mesylate 6 PIKfyve
MD2-TLR4-IN-1 2 TLR4,TNF-α
Danirixin (GSK1325756) 2 CXCR2
Resatorvid (TAK-242) 65 TLR4,NO,TNF-α
Apilimod (STA-5326) 19 PIKfyve
LMT-28 1
Atractylodin 0 NAAA
Triolein 0 ROS,MMP-1
Ac-YVAD-cmk 5
Diethyl phosphate 1
RCM-1 5 STAT6,FOXM1,β-catenin
Stylopine 0 COX-2,TNF-α,NO
Myrislignan 1 NF-κB,COX-2,iNOS
NE 52-QQ57 2 iNOS,TNF-α,PGE2
PKR-IN-C16 9 PKR
(3R,8S)-Falcarindiol 3 STAT,ERK,JNK
Gardenoside 1 P2X7 Receptor,P2X3 receptor,NF-κB
T-5224 23 c-Jun,c-Fos/AP-1,Adamts-5
IQ 3 1 TNF-α,JNK3,JNK1
Isuzinaxib (APX-115 free base) 2 TNFα,MCP-1/CCL2,NOX2
AUDA 1 p38,Smad3,TGF-β
SAR-20347 1 IFN-α,TYK2,JAK1
SU 5201 0
Madecassic acid 3 TNF-α,COX-2,iNOS
Homoplantaginin 1 NF-κB,IKKβ,TNF-α
2',5'-Dihydroxyacetophenone 1 NF-κB,ERK1/2,iNOS
Forsythoside B 0 NF-κB,TNF-alpha,IκB
Mulberroside A 0 NF-κB,Caspase-1,NALP3
Chelidonic acid 0 glutamate decarboxylase,Caspase-1,NF-κB
4-Methylesculetin 2 MPO
Muscone 4 TNF-α,NLRP3 inflammasome,NF-κB
Ossirene (AS101) 16
Methylthiouracil 1 ERK1/2,NF-κB,TNF-α
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Mepolizumab (Anti-IL-5) is a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against interleukin-5 (IL-5) with anti-asthmatic and potential immunosuppressive activity. MW: 145.5 kD.

Product Details

CAS No. 196078-29-2
Molecular Weight 145.5 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT06501807 RECRUITING Drug: Biologic treatments available in Chronic Rhinosinusiti Rhinosinusitis Chronic; Nasal Polyps University Hospital, Lille 2024-07-11
NCT07200336 NOT_YET_RECRUITING Drug: Mepolizumab Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Eye & ENT Hospital of Fudan University 2025-10-08 PHASE4
NCT05979051 RECRUITING Drug: SHR-1703|Drug: Mepolizumab Injection Eosinophilic Granulomatosis With Polyangiitis Guangdong Hengrui Pharmaceutical Co., Ltd 2023-11-16 PHASE2; PHASE3
NCT07749001 NOT_YET_RECRUITING Drug: Mepolizumab 100 MG Injection COPD (Chronic Obstructive Pulmonary Disease) Western University, Canada 2026-10-01 PHASE4
NCT07268313 RECRUITING Drug: DUPIXENT®|Drug: NUCALA® Nasal Polyps Rigshospitalet, Denmark 2025-04-03 PHASE4
NCT06680947 ACTIVE_NOT_RECRUITING Drug: 610|Drug: 610|Drug: Placebo Asthma Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. 2024-12-20 PHASE2

(data from https://clinicaltrials.gov, updated on 2026-05-18)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.